MetaCap

Kamada (KMDA) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Kamada (KMDA) over the past year, gaining 119.7% versus a gain of 14.7%. Over five years, KMDA leads with a +22.7% price change compared with -52.0% for STTK. Shattuck Labs is the larger company by market cap ($454.2 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs -82.5%).

Kamada pays a dividend yielding 7.24%, while Shattuck Labs does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -4880.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KMDA+14.67%STTK+119.70%
+312%+148%-16%
Nov 21, 20251 yearNov 20, 2026
KMDA+38.21%STTK-52.55%
+66%-17%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KMDA versus STTK key metrics
MetricKMDASTTK
Share price$7.74$4.46
Market cap$446.85M$454.22M
1-day change-1.15%-1.98%
YTD return+9.63%+22.19%
1-year return+14.67%+119.70%
5-year return+22.66%-51.99%
P/E ratio (TTM)20.37—
Forward P/E13.34—
EPS (TTM)$0.38$-0.47
Dividend yield7.24%0.00%
Annual dividend$0.56$0.00
Revenue (latest FY)$180.46M$1.00M
Revenue growth (YoY)+12.12%-82.52%
Net income (latest FY)$20.20M$-48.81M
Gross margin42.34%—
Operating margin14.54%-5150.80%
Net margin11.19%-4880.90%
52-week high$9.35$8.33
52-week low$6.63$1.93
Distance from 52-week high-17.22%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.65%+245.29%
Average volume121.87K1.20M
Shares outstanding57.73M101.84M
Employees46240
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed KMDA by 105.0 percentage points over the past year.
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
  • Kamada grew revenue faster in its latest fiscal year (+12.12% vs -82.52%).

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

KMDA vs STTK FAQ

Which is bigger, Kamada or Shattuck Labs?

Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $446.85M for Kamada (KMDA).

Which stock has performed better over the past year, KMDA or STTK?

STTK returned +119.70% over the past 12 months, compared with +14.67% for KMDA (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Kamada or Shattuck Labs?

Kamada pays a dividend yielding 7.24%, while Shattuck Labs does not currently pay a regular dividend.

Are Kamada and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons